Alligator Bioscience has announced an approved IND (Investigational new Drug) for the CD40 targeting antibody mitazalimab.
IND approval by the US Food and Drug Administration (FDA) is a prerequisite to start clinical trials in the USA. Recently, new benchmark data was published showing that mitazalimab has the potential to be best-in-class in the CD40 field, states the company. The comparison demonstrated the potent immune-activating properties and anti-tumor effects of mitazalimab.
The IND opens up for later expansion in the US
“While the upcoming clinical Phase Ib/II study in pancreatic cancer, OPTIMIZE-1, will be starting in Europe, the IND opens up for later expansion in the US. This is essential for the future success of the product”, said Per Norlén, CEO of Alligator Bioscience,” says Per Norlén, CEO of Alligator Bioscience. “Our key focus right now is to complete the submission of the CTA for start of OPTIMIZE-1 in the EU.”
The mitazalimab drug candidate has previously reported positive clinical data from a Phase I study performed by Janssen Biotech Inc., displaying a manageable safety profile as well as early signs of efficacy.
Photo of Per Norlén: Jenny Leyman